Ingénieur de Recherche et Développement

!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!"#$"%&'()*+,%!-.,%!-"/0.%% % '1231456/%75%859-5/9-5%5:%.3;5$#<<5051:%
"#!$%&!'(%)!'*%++&,!♦!-./00!1234$5!♦!67(89&!
:;)<!!0=!>=!0"!=?!""!♦!4@(A)<!B(*)(CDA(+*8EF(G**HA,!!!!
!8*='>?%
Pharmacologue spécialisée dans le cadre de la personnalisation de la chimiothérapie pour les tumeurs
solides (colorectal, du sein, de l'ovaire).
Plus de 10 ans d'expérience dans la définition des markers génétiques et biochimiques liés à la variation de
la réponse à la chimiothérapie. Compétente dans l’évaluation de l'adaptation de dose au cours des
traitements selon le profil génétique et métabolique du patient.
Très bonnes capacités d'analyse des problèmes et définition des solutions possibles. Excellentes
compétences organisationnelles en respectant le délai fixé pour chaque projet.
Compétences:
! Définition d’une stratégie de personnalisation de la thérapie.
! Définition, production et assistance technique et scientifique de kits de diagnostic in vitro.
Techniques maîtrisées :
! Biologie moléculaire: extraction ADN et ARN, PCR, RT-PCR, discrimination allélique (RLFP,
Pyroséquençage, TaqMan, Veracode Bead Express), NGS (IonTorrent), analyse d’expression de
l’ARN, séquençage classique (Sanger), clonage en mutagénèse dirigée.
! Biochimie: extraction des analytes dès matrices biologiques (SLE, LLE), analyses en
chromatographie (HPLC, UPLC, LC-MS/MS).
!
!
8?)@A?%.?%B(88'?8?%)B'?+C'='D@?!
'+E?+'?@8%.?%8?BF?8BF?%G%B..%%
I8AJ&7+A,;!KL18M&7+!N!6(9%),;!K&!O;K&9A8&!!
18M&7+!P!67(89&!
Octobre(2014(-(En(cours(
!
'+E?+'?@8%.?%8?BF?8BF?%H%B*+)@>C(+C?%)B'?+C'='D@?%
QR'O!N!Q89*!R7%M!'&7+*8()AS&K!O&KA9A8&!!
18M&7+!N!67(89&!
!
B*G=*+.(C8'B?%?C%B*+)@>C(+C?%)B'?+C'='D@?%
Septembre(2012(–(Septembre(2014(
(
(
Décembre(2009(–(En(cours(
'G(7@(RT1342!P!'*)*!:&98*)*MA9*!!
'*7K&8*8&!N!T,()A&!
!
B*+C8(C%!*)CG.*BC*8(C%%
U&8,7*!KA!$AV&7A@&8,*!Q89*)*MA9*!P!U&8,7&!K&!W%,,&!9*8,7&!)&!U(89&7!!
1JA(8*!X'2Y!P!T,()A&!
Janvier(2009(–(Août(2012(
!
.*BC*8(C%.I@+'J?8)'C?%?+%!F(8A(B*>*E'?%?C%C*K'B*>*E'?%
I8AJ&7+A,;!K&+!4,%K&+!K&!'(K%&!&8!9*))(D*7(,A*8!(J&9!)&!U&8,7*!KA!
$AV&7A@&8,*!Q89*)*MA9*!
1JA(8*!X'2Y!P!T,()A&!
Septembre(2005(-(Décembre(2008(
!
&*@8)?%.I?C@.?%%
U&8,7*!KA!$AV&7A@&8,*!Q89*)*MA9*!P!U&8,7&!K&!W%,,&!9*8,7&!)&!U(89&7!!
1JA(8*!X'2Y!P!T,()A&!
Octobre(2003(–(Août(2005(
!
)C(E?%!8*=?))'*++?>%%%
'G(7@(9A&!Z!R&!:*8A![!
'*7K&8*8&!P!T,()A&!
Avril(2002(–(Janvier(2003(
!

!
!
B*A!?C?+B?)%C?BF+'D@?)%!8*=?))'*++?>>?)%
)59:4#1%.3;5$#<<5051:%'176L:/45$M!
- 18()F+&! K&! )(! K&@(8K&! A8K%+,7A&))&!<! K;VA8A,A*8! K&+! B7*9&++%+! 8;9&++(A7&! B*%7! )&! K;J&)*BB&@&8,! K&!
8*%J&(%\!B7*K%A,+!*%!)](@;)A*7(,A*8!K&+!B7*K%A,+!&8!B7*K%9,A*8!^!
- 18()F+&!K&+!K*88;&+!,&9G8A_%&+!&,!;9*8*@A_%&+!8;9&++(A7&+!B*%7!J()AK&7!9G(_%&!;,(B&!K%!B7*`&,!^!
- R;VA8A,A*8!K&!8*%J&(%\!B7*,*9*)&+!&\B;7A@&8,(%\!^!
- R;VA8A,A*8!K&+!@;,G*K&+!KL(8()F+&!K&+!B7*K%A,+!^!
- Q7M(8A+(,A*8!&,!9**7KA8(,A*8!K&+!,&+,+!K&!V(D7A9(,A*8!^!
- 4J()%(,A*8!K&+!7;+%),(,+!&,!9(B(9A,;!K&!@&,,7&!&8!a%J7&!)&+!(@;)A*7(,A*8+!8;9&++(A7&+!^!
- $;K(9,A*8!K&+!K*9%@&8,+!,&9G8A_%&+!VA8()&+!X+B;9AVA9(,A*8+!B*%7!)&+!@(,Ab7&+!B7&@Ab7&+#!B7*K%A,+!VA8A+#!)&+!
B(7(@b,7&+!&,!)&!9*8,7c)&!V(D7A9(,A*8#!)(!9&7,AVA9(,A*8!U4Y!^!
- $&9G&79G&! DAD)A*M7(BGA_%&! 9*8+,(8,&! +%7! )&+! 8*%J&(%,;+! K%! @(79G;!<! @;,G*K*)*MA&+#! (BB(7&A)+!
+9A&8,AVA_%&+#!dA,!KA(M8*+,A_%&+!&8!JA,7*H!
!
)59:4#1%859-5/9-5M!
- U*8+,(8,&!@A+&!e!`*%7!K&+!B%D)A9(,A*8+!7&)(,AJ&+!(%\!B7*`&,+!&8!9*%7+!^!
- R;VA8A,A*8!K&+!@(7_%&%7+!XM;8;,A_%&+!&,!DA*9GA@A_%&+Y!9*77;);+!(J&9!)(!@*);9%)&!KLA8,;7f,!(VA8!K&!K;VA8A7!
%8&!+,7(,;MA&!K&!B&7+*88()A+(,A*8!K%!,7(A,&@&8,!^!
- OA+&! &8! B)(9&! K&+! (8()F+&+! M;8;,A_%&+! (J&9! B)%+A&%7+! ,&9G8A_%&+! ,&))&+! _%&! )(! 'U$! &8! ,&@B+! 7;&)#! )&!
+;_%&8g(M&! 5(8M&7#! )&!'F7*+;_%&8g(M&#!)&! +;_%&8g(M&! e!G(%,! K;DA,! X235! P! T*8! :*77&8,YH! 4J()%(,A*8! K&+!
7;+%),(,+!(J&9!)&+!B7A89AB(%\!*%,A)+!K&!)(!DA*A8V*7@(,A_%&H!U)*8(M&!B(7!@%,(M;8b+&!KA7AM;&H!RA+97A@A8(,A*8!
());)A_%&!X:(_@(8Y!&,!%,A)A+(,A*8!K&+!A8+,7%@&8,!e!G(%,!K;DA,!Xh&7(9*K&!i&(K+!4\B7&++!N!T))%@A8(YH!
- OA+&! &8! B)(9&! K&+! (8()F+&+! BG;8*,FBA_%&+! (J&9! +B&9,7*@;,7A&! K&! @(++&! &,! Ij'WU<! K;J&)*BB&@&8,! K&!
@;,G*K&+!K]&\,7(9,A*8!X)A_%AK&k)A_%AK&#!+*)AK&k)A_%AK&Y!&,!K](8()F+&H!
!!
!
!
%
(@C8?)%B*A!?C?+B?)%%
- U*88(A++(89&+!A8V*7@(,A_%&+!<!OA97*+*V,!lA8K*m+#!OA97*+*V,!QVVA9&!XB*%7!lA8K*m+!&,!O(9Y#!'*m&7!'*A8,#!
$&V&7&89&!O(8(M&7#!48K!8*,&!B*%7!O(9H!!
- I,A)A+(,A*8!_%*,AKA&88&!KLT8,&78&,#!9*88(A++(89&!K&+!D(8_%&+!K&!K*88;&+!+9A&8,AVA_%&+!X'%D@&K#!'G(7@3ni#!
j(BO(BY!!
- U*88(A++(89&!&,!%,A)A+(,A*8!D(+A_%&!K&!B7*M7(@@&+!B*%7!)&+!(8()F+&+!+,(,A+,A_%&+!<!$#!37(BG!B(KH!
- 489(K7&@&8,!K&+!;,%KA(8,+!N!+%AJA!K&+!B7*`&,+!K&!+,(M&!B*%7!O(+,&7!/!&,!"H!
=*8A(C'*+%
%
R*9,*7(,!&8!'G(7@(9*)*MA&!&,!:*\A9*)*MA&!!N!I8AJ&7+A,;!K&!'(K%&!
!
(
2005-2008(
(
(
(
2003(
5*%,&8(89&!B%D)A_%&! )&! "0! 1J7A)! "00.! N! Z!'G(7@(9*M&8&,A9+! *V! 9F,*9G7*@&+! A8! D7&(+,!
9(89&7!,7&(,@&8,![!!
!
'GR!
RAB)c@&!KL4,(,!&8!'G(7@(9A&!N!I8AJ&7+A,;!K&!'(K%&!
o%()AVA9(,A*8!e!)(!B7*V&++A*8!K&!BG(7@(9A&8!
2*,&!<!"">k"p0!
!
!
'G(7@R!
O(+,&7!"!&8!UGA@A&!&,!:&9G8*)*MA&!'G(7@(9&%,A_%&!!N!I8AJ&7+A,;!K&!'(K%&!
!
5*%,&8(89&! B%D)A_%&! )&! "?! q%A8! "00r! N! Z!'G(7@(9*M&8&,A9+! (+B&9,+! A8J*)J&K! A8! 9*)*8!
9(89&7! ,G&7(BFH! $*)&! *V! I7AKA8! 1K&8*+F)! KABG*+BG(,&! M)%9%7*8*+F)! ,7(8+V&7(+&!
XI3:Y!B*)F@*7BGA+@+[!
2*,&!<!/0?k//0
'G(7@R!
1997-2003(
!
!
(
!
!
!

!
!
!@&&>'B(C'*+)%?C%B*AA@+'B(C'*+)%
!6NN$49":4#1LM!
- “Dihydropyrimidine(dehydrogenase(and(fluoropyrimidines:(a(review(of(current(dose(adaptation(practices(and(the(
impact(on(the(future(of(personalized(medicine(using(5-fluorouracil”!i*A+K7*8PU&))&!OH#!&4"L#1%!O#!3(@&)A8!4H#!(8K!
1)(A8!O*7&)H!85;45P#!U*)*7&9,()!U(89&7#!QRST,!"X=Y<p-.Ppp>H!
- sPolymorphic( thymidylate( synthase( gene( impacts( on( overall( survival( of( patients( with( epithelial( ovarian( cancer(
after( platinum-based( chemotherapy”( &4"L#1% !O,!hA+&8,A8! OH#! :()(@A8A! $H#! 5,*B(7! 1H#! 3A*7K(! 3H#! W%9A(! 4H#!
U(@B(M8%,,(!4H#!:*VV*)A!3H(85L5"/9-%"/:49$5,!'G(7@(9*M&8*@A9+#!QRSQ,%/rX/-Y</=0.P/=/.%.!
- “microRNA( pharmacogenomics:( the( new( frontier( for( personalized( medicine( in( cancer?”( R7&%++A! 4H#! &4"L#1% !O,!
:*VV*)A!3H#!(8K!U&99GA8!4H!85;45P,!'G(7@(9*M&8*@A9+#!QRSQ,%/rX/-Y</=rpP/=p0.!
- “Nucleotide( excision( repair( gene( variants( and( association( with( survival( in( osteosarcoma( patients( treated( with(
neoadjuvant( chemotherapy”!&4"L#1% !H#! j(,,A8M&7! UO#! T88*9&8,A! 6H#! :()(@A8A! $H#! 1)D&7MGA8A! OH#! 59*,)(8KA! nH#!
t(8%++*!UH#!5&77(!OH#!(8K!:*VV*)A!3H!85L5"/9-%"/:49$5,!'G(7@(9*M&8*@A9+!q#!QRSS,%/"X=Y<-?=P->r.!
- (“Tumor( response( is( predicted( by( patient( genetic( profile( in( rectal( cancer( patients( treated( with( neo-adjuvant(
chemo-radiotherapy”!U&99GA8!4#!1M*+,A8A!O#!'%99A(7&))A!5#!R&!'(*)A!1#!U(8S*8A&7A!h#!5AM*8!$#!R&!O(,,A(!4#!67A+*!OW#!
&4"L#1%!#!hA+&8,A8!O#!2A,,A!R!(8K!:*VV*)A!3H!85L5"/9-%"/:49$5,!'G(7@(9*M&8*@A9+!q#!QRSR,!//XrY<"/-P""=.!
- “Drug(interactions(among(the(epidermal(growth(factor(receptor(inhibitors,(other(biologics(and(cytotoxic(agent”!
hA+&8,A8!OH#!&4"L#1%!O,!:*VV*)A!3H!85;45P#!'G(7@(9*)!:G&7H#!QRSR,%/">X/Y<>"P.0H!
- sEffect( of( TP53( Arg72Pro( and( MDM2( SNP309( Polymorphisms( on( the( Risk( of( High-Grade( Osteosarcoma(
Development(and(Survival”(:*VV*)A!3H#!&4"L#1%!O,!$%++*!1H#!R&!O(,,A(!4H#!U&99GA8!4H#!j(,,A8M&7!UHOH#!'(+&))*!OH#!
1)D&7MGA8*!OH#!6&77(7A!UH#!59*,)(8KA!nH#!'A99A!'H!(8K!5&77(!OH%85L5"/9-%"/:49$5,!U)A8!U(89&7!$&+#!QRRU,!/pX/0Y<rpp0P
rpp=.!
- “Predictive(Role(of(the(UGT1A1,(UGT1A7,(and(UGT1A9(Genetic(Variants(and(Their(Haplotypes(on(the(Outcome(of(
Metastatic( Colorectal( Cancer( Patients( Treated( With( Fluorouracil,( Leucovorin,( and( Irinotecan.”( U&99GA8! 4#!
T88*9&8,A!6#!R]18K7&(!O#!U*7*8(!3#!R&!O(,,A(!4#!&4"L#1%!#!i%*8(K*88(!1#!:*VV*)A!3H!85L5"/9-%"/:49$5#!q*%78()!*V!
U)A8!Q89*)#!QRRU,%"?X/pY<"-p?P"-=pH!
- “UGT1A1*28(and(other(UGT1A(polymorphisms(as(determinants(of(irinotecan(toxicity”,%&4"L#1%!O,%O(+A&7!5H!(8K!
:*VV*)A!3H!85;45P#!q!UG&@*,G&7#!QRRV,%"0!X"Y</p>P/=p.!
- !sPharmacology(of(epidermal(growth(factor(inhibitorsu#!:*VV*)A!3H#!R&!O(,,A(!4H#!U&99GA8!4H#!&4"L#1%!O#!O(+A&7!5H#!
U*7*8(!3HH!85;45P,!T8,!q!iA*)!O(7d&7+#!QRRW#!5%BB)!-#!5"-P5r.H!
- (“The( role( of( UGT1A1*28( polymorphism( on( the( pharmacodynamics( and( pharmacokinetics( of( irinotecan( in(
patients(with(metastatic(colorectal(cancer”,!:*VV*)A!3H#!U&99GA8!4H#!U*7*8(!3H#!$%++*!1H#!i%*8(K*88(!1H#!RL18K7&(!
OH#! '(+&,,*! WHOH#! '&++(! 5H#! 477(8,&! RH#! R&! '(8MG&7! hH#! 3A%+,*! OH#! 3(A*8! 6H#! 5(8K7A! 'H#! 3())AMA*8A! 4H#! i*8%7(! 5H#!
i*99()*8!OH#!&4"L#1%!O,!67%+,(9A!5H%85L5"/9-%"/:49$5,!q!*V!U)A8!Q89*)#!QRRX#!"-!X/.Y<r0=/Pr0=>H!
- vCarboxylesterase(isoform(2(mRNA( _expression(in(peripheral(blood(mononuclear(cells(is(a(predictive(marker(of(
the(irinotecan(to(SN38(activation(step(in(colorectal(cancer(patientsv#!U&99GA8!4H#!U*7*8(!3H#!O(+A&7!5H#!&4"L#1%!O#!
U(,,(7*++A! 3H#! 67%+,(9A! 5H#! i%*8(K*88(! 1H#! U*)%++A! 1H!(8K! :*VV*)A! 3H!85L5"/9-% "/:49$5,!U)A8! U(89&7! $&+#! QRRY,!
//X/.Y<=.0/P=.0?H!
- sSarcomas(and(pharmacogeneticsu!&4"L#1!!O!(8K:*VV*)A!3H!85;45P#!'G(7@(9*M&8*@A9+P6%,%7&!O&KA9A8&#!QRRY#!
=X=Y<p>pP=0/O!
%

!
!
Audition et séminaires:!!
- “TAILORCap:( les( sciences( “omiques”( au( service( de( la( personnalisation( des( traitements( oncologiques( avec(
capécitabine”!N!"674:4#1!(%B7b+!K%!U*@A,;!:&9G8A_%&!$&++&77;!K%!U*89*%7+!O*8KA()!KLT88*J(,A*8!XUOTY!"0/-!N!
V(+&!VA8()&#!iBAV7(89&!'(7A+!"=%Z641!QRS[O!
- “Personnalisation(des(traitements(aux(fluoropyrimidines:(faisabilité(en(diagnostique(clinique”!N!</3L51:":4#1%L6/%
<$"95%K&+!K*88;+!+9A&8,AVA_%&+!&,!K&+!B7*K%A,+!K&!QR'O!!
" WF*8!"0!A"\%QRS[!N!U&8,7&!W;*8!i;7(7K!
" i&7)A8!//!=3;/45/%QRS[!P!T345!T8+,A,%,!3@Dj!
" O*8(9*!/0!=3;/45/%QRS[!P!U)A8A_%&!%8AJ&7+A,(A7&!O%8A9G!
" U*)*M8&!0-!=3;/45/%QRS[!P!i&7%V+J&7D(8K!K&7!8A&K&7M&)(++&8&8!jw@(,*)*M&8!x!Q8d*)*M&8!A8!R&%,+9G)(8K!
&HhH!Xi2jQ!&HhHY!!
" U(&8!0.%Z"1;45/%QRS[%N!U&8,7&!67(8g*A+!i(9)&++&
- “Personnalisation(des(traitements(aux(fluoropyrimidines:(faisabilité(en(diagnostique(clinique”!N!</3L51:":4#1%51%
$4215%K&+!K*88;+!+9A&8,AVA_%&+!&,!K&+!B7*K%A,+!K&!QR'O!!
" i7;+A)!/r!Z641%QRS[%N!I8AJ&7+AK(K& 6&&J()&!
" WF*8!/>!.3950N/5%QRS[!P!U&8,7&!j*+BA,()A&7!'A&77&!Q%K*,!
%
Communications orales dans des congrès:!!
- “Single(Nucleotide( Polymorphism( in( DNA( repair(genes( associated(with( cisplatin(resistance(in( osteosarcoma”!!O%
&4"L#1#! UHOH! j(,,A8M&7#! 6H! OA9G&)(99A#! OH! 6(8&))A#! 4H! :(J(8,A#! hH! 5&7*#! 5H! h&))(#! OH! 5&77(#! 3H! :*VV*)A#! 4%7*B&(8!
q*%78()!*V!U(89&7#!1D+H!/0=r#!i(79&))*8(!?P/0!`%A))&,!QRSQO!
- “Pharmacogenetics(and(osteosarcoma”!N!1+,*7A(!j*,&)!K&!37(K*!X3QY#!>!*9,*D7&!QRSSO!
- “4th( STAR( network( integrated( and( traslational( treatment( in( gastroinetstinal( cancer”!5,(7G*,&)! 4\9&)+A*7! K&!
i*)*M8(#!/0!K;9&@D7&!QRRUO!
- “Ovarian(Carcinoma:(therapeutic(updates”(S()(!'*)A97&,A!3*)V!U)%D!K&!U(+,&)!KL1JA(8*!X'2Y#!"?!8*J&@D7&!QRRUH!
- sMDM2(309(T>G(polymorphism(in(human(sarcomas!s#!!O%&4"L#1,%5H!O(+A&7#!OH!5&77(#!nH!59*,)(8KA#!4H!U&99GA8#!6H!
5(7,*7#!3H!iA+9*8,A8!&!3H!:*VV*)AH!/>,G!4Q$:UP2UTP11U$H!'7(M%&#!?P/0!8*J;@D7&!QRRXH!
!
%